Publication: Advances and recent developments in asthma in 2020
dc.contributor.buuauthor | Cevhertaş, Laçin | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0003-2287-3569 | tr_TR |
dc.contributor.scopusid | 57216918051 | tr_TR |
dc.date.accessioned | 2022-11-24T08:55:53Z | |
dc.date.available | 2022-11-24T08:55:53Z | |
dc.date.issued | 2020-09-30 | |
dc.description | Bu çalışmada 22 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. | tr_TR |
dc.description.abstract | In this review, we discuss recent publications on asthma and review the studies that have reported on the different aspects of the prevalence, risk factors and prevention, mechanisms, diagnosis, and treatment of asthma. Many risk and protective factors and molecular mechanisms are involved in the development of asthma. Emerging concepts and challenges in implementing the exposome paradigm and its application in allergic diseases and asthma are reviewed, including genetic and epigenetic factors, microbial dysbiosis, and environmental exposure, particularly to indoor and outdoor substances. The most relevant experimental studies further advancing the understanding of molecular and immune mechanisms with potential new targets for the development of therapeutics are discussed. A reliable diagnosis of asthma, disease endotyping, and monitoring its severity are of great importance in the management of asthma. Correct evaluation and management of asthma comorbidity/multimorbidity, including interaction with asthma phenotypes and its value for the precision medicine approach and validation of predictive biomarkers, are further detailed. Novel approaches and strategies in asthma treatment linked to mechanisms and endotypes of asthma, particularly biologicals, are critically appraised. Finally, due to the recent pandemics and its impact on patient management, we discuss the challenges, relationships, and molecular mechanisms between asthma, allergies, SARS-CoV-2, and COVID-19. | en_US |
dc.description.sponsorship | Sanofi & Regeneron | en_US |
dc.description.sponsorship | GlaxoSmithKline | en_US |
dc.description.sponsorship | European Commission | en_US |
dc.description.sponsorship | Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | en_US |
dc.description.sponsorship | Christine Kühne – Center for Allergy Research and Education | en_US |
dc.identifier.citation | Cevhertaş, L. vd. (2020). "Advances and recent developments in asthma in 2020". Allergy: European Journal of Allergy and Clinical Immunology, 75(12), 3124-3146. | en_US |
dc.identifier.endpage | 3146 | tr_TR |
dc.identifier.issn | 0105-4538 | |
dc.identifier.issue | 12 | tr_TR |
dc.identifier.pubmed | 32997808 | tr_TR |
dc.identifier.scopus | 2-s2.0-85092593379 | tr_TR |
dc.identifier.startpage | 3124 | tr_TR |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/full/10.1111/all.14607 | |
dc.identifier.uri | https://doi.org/10.1111/all.14607 | |
dc.identifier.uri | http://hdl.handle.net/11452/29554 | |
dc.identifier.volume | 75 | tr_TR |
dc.identifier.wos | 000577623000001 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Allergy: European Journal of Allergy and Clinical Immunology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Asthma biomarkers | en_US |
dc.subject | Asthma phenotypes | en_US |
dc.subject | Biological therapeutics | en_US |
dc.subject | Comorbidities | en_US |
dc.subject | Covid-19 | en_US |
dc.subject | Allergen immunotherapy | en_US |
dc.subject | Arginase inhibitors | en_US |
dc.subject | Blood eosinophils | en_US |
dc.subject | Eeeaci guidelines | en_US |
dc.subject | Food allergy | en_US |
dc.subject | Rhinits | en_US |
dc.subject | Management | en_US |
dc.subject | Omalizumab | en_US |
dc.subject | Pathology | en_US |
dc.subject | Paradigm | en_US |
dc.subject | Allergy | en_US |
dc.subject | Immunology | en_US |
dc.subject.emtree | Biological marker | en_US |
dc.subject.emtree | Protein | en_US |
dc.subject.emtree | Biological marker | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Allergic disease | en_US |
dc.subject.emtree | Asthma | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Comorbidity | en_US |
dc.subject.emtree | Coronavirus disease 2019 | en_US |
dc.subject.emtree | Dietary supplement | en_US |
dc.subject.emtree | Disease severity | en_US |
dc.subject.emtree | Dysbiosis | en_US |
dc.subject.emtree | Environment | en_US |
dc.subject.emtree | Environmental exposure | en_US |
dc.subject.emtree | Epigenetics | en_US |
dc.subject.emtree | Exposome | en_US |
dc.subject.emtree | Heredity | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Obesity | en_US |
dc.subject.emtree | Pandemic | en_US |
dc.subject.emtree | Personalized medicine | en_US |
dc.subject.emtree | Phenotype | en_US |
dc.subject.emtree | Prevalence | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Review | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Severe acute respiratory syndrome coronavirus 2 | en_US |
dc.subject.emtree | Sex difference | en_US |
dc.subject.emtree | Signal transduction | en_US |
dc.subject.emtree | Smoking | en_US |
dc.subject.emtree | Asthma | en_US |
dc.subject.emtree | Hypersensitivity | en_US |
dc.subject.mesh | Asthma | en_US |
dc.subject.mesh | Biomarkers | en_US |
dc.subject.mesh | Comorbidity | en_US |
dc.subject.mesh | Covid-19 | en_US |
dc.subject.mesh | Dysbiosis | en_US |
dc.subject.mesh | Exposome | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Pandemics | en_US |
dc.subject.mesh | Phenotype | en_US |
dc.subject.mesh | Precision medicine | en_US |
dc.subject.mesh | Risk factors | en_US |
dc.subject.scopus | Benralizumab; Asthma; Fractional Exhaled Nitric Oxide | en_US |
dc.subject.wos | Allergy | en_US |
dc.subject.wos | Immunology | en_US |
dc.title | Advances and recent developments in asthma in 2020 | en_US |
dc.type | Article | |
dc.wos.quartile | Q1 | en_US |
dspace.entity.type | Publication |